These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 28234925)

  • 1. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.
    Ramachandran RK; Sørensen MD; Aaberg-Jessen C; Hermansen SK; Kristensen BW
    PLoS One; 2017; 12(2):e0172234. PubMed ID: 28234925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors.
    Nakada M; Nakamura H; Ikeda E; Fujimoto N; Yamashita J; Sato H; Seiki M; Okada Y
    Am J Pathol; 1999 Feb; 154(2):417-28. PubMed ID: 10027400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma.
    Nakada M; Kita D; Futami K; Yamashita J; Fujimoto N; Sato H; Okada Y
    J Neurosurg; 2001 Mar; 94(3):464-73. PubMed ID: 11235952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas.
    Thorns V; Walter GF; Thorns C
    Anticancer Res; 2003; 23(5A):3937-44. PubMed ID: 14666700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of matrix metalloproteinases and their inhibitors in human brain tumors.
    Kachra Z; Beaulieu E; Delbecchi L; Mousseau N; Berthelet F; Moumdjian R; Del Maestro R; Béliveau R
    Clin Exp Metastasis; 1999; 17(7):555-66. PubMed ID: 10845554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors.
    Nakagawa T; Kubota T; Kabuto M; Sato K; Kawano H; Hayakawa T; Okada Y
    J Neurosurg; 1994 Jul; 81(1):69-77. PubMed ID: 8207529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.
    Zhang K; Li C; Liu Y; Li L; Ma X; Meng X; Feng D
    Neuroradiology; 2007 Nov; 49(11):913-9. PubMed ID: 17763847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
    Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
    Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase-2 and -9 expression in astrocytic tumors.
    Kunishio K; Okada M; Matsumoto Y; Nagao S
    Brain Tumor Pathol; 2003; 20(2):39-45. PubMed ID: 14756439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
    Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
    Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms.
    Jäälinojä J; Herva R; Korpela M; Höyhtyä M; Turpeenniemi-Hujanen T
    J Neurooncol; 2000; 46(1):81-90. PubMed ID: 10896208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas.
    Lucio-Eterovic AK; Cortez MA; Valera ET; Motta FJ; Queiroz RG; Machado HR; Carlotti CG; Neder L; Scrideli CA; Tone LG
    BMC Cancer; 2008 Aug; 8():243. PubMed ID: 18713462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors.
    Krogh Petersen J; Jensen P; Dahl Sørensen M; Winther Kristensen B
    PLoS One; 2016; 11(12):e0169129. PubMed ID: 28030635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases in human gliomas: activation of matrix metalloproteinase-2 (MMP-2) may be correlated with membrane-type-1 matrix metalloproteinase (MT1-MMP) expression.
    Hur JH; Park MJ; Park IC; Yi DH; Rhee CH; Hong SI; Lee SH
    J Korean Med Sci; 2000 Jun; 15(3):309-14. PubMed ID: 10895974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas.
    Haapasalo J; Nordfors K; Granberg KJ; Kivioja T; Nykter M; Haapasalo H; Soini Y
    Histol Histopathol; 2018 Aug; 33(8):791-801. PubMed ID: 29441509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated leukocyte cell adhesion molecule is expressed in neuroepithelial neoplasms and decreases with tumor malignancy, matrix metalloproteinase 2 expression, and absence of IDH1R132H mutation.
    Allmendinger O; Trautmann K; Mittelbronn M; Waidelich J; Meyermann R; Tatagiba M; Schittenhelm J
    Hum Pathol; 2012 Aug; 43(8):1289-99. PubMed ID: 22304788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the Annexin A1 and its correlation with matrix metalloproteinases and the receptor for formylated peptide-2 in diffuse astrocytic tumors.
    Tadei MB; Mayorquim MV; de Souza CB; de Souza Costa S; Possebon L; Souza HR; Iyomasa-Pilon MM; Geromel MR; Girol AP
    Ann Diagn Pathol; 2018 Dec; 37():62-66. PubMed ID: 30286327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.